OphthalmoPro
OphthalmoPro provides clinicians with advanced technologies that support the detection and management of macular disease. The new Microclear SKY Whole Eye imaging system delivers comprehensive retinal imaging with high-resolution visualisation of the posterior segment, in the form of widefield fundus photography (135°) combined with widefield optical coherence tomography, assisting clinicians in identifying structural changes associated with macular conditions such as age- related macular degeneration (AMD).
Complementing these diagnostic capabilities, Espansione’s AMD Eye-light device is now officially available in New Zealand, offering photobiomodulation light- based therapy for the management of early to intermediate dry AMD. Together, these technologies support a more integrated approach to macular care, enabling improved screening, monitoring, and non-invasive treatment pathways.
By combining advanced imaging with emerging therapeutic options, OphthalmoPro aims to support earlier detection and improve clinical management of macular disease.
Why Choose MonacoPRO?
• Sharp, detailed Spectral Domain OCT imaging.
• New AreaAssist tool.
Automates and simplifies retinal imaging, saving valuable time, and
• Reference database.
Improves glaucoma detection through optic nerve head analysis.
Vabysmo
(RIGHT)
Vabysmo (faricimab) is the only bispecific antibody registered with the Australian Registry of Therapeutic Goods for neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO). on the Pharmaceutical Benefits Scheme (PBS) for nAMD and DMO.
This intravitreal treatment works on two distinct pathways, specifically recognising and blocking angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF). After the four initial four-weekly loading doses, the frequency of ongoing injections may be extended up to every 16 weeks based on the patient’s anatomic and/or visual outcomes. Contact: Roche Account Manager
Vabysmo ▼ is listed on the PBS for nAMD and DMO. Refer to PBS Schedule for full authority information. ▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information.
For full information see page 9. M-AU-00002420. Prepared Mar 24.
(LEFT)